Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.44 |
| ▸ | TTK | P33981 | 4/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930788 | 0.95 | KDR (0.50) | DYRK1AKDRNUAK1BRD4BRDT | |
| Trifluoroacetic Acid SCHEMBL2934334 | 0.92 | LRRK2 (0.51) | DYRK1ATTKLRRK2 | |
| SCHEMBL2927025 | 0.92 | KDR (0.47) | DYRK1AKDRNUAK1BRD4BRDT | |
| Trifluoroacetic Acid SCHEMBL2928635 | 0.91 | DYRK1A (0.47) | DYRK1AKDRNUAK1BRD4BRDT | |
| SCHEMBL14294231 | 0.88 | LRRK2 (0.49) | TTKLRRK2 | |
| Trifluoroacetic Acid SCHEMBL2933585 | 0.87 | KDR (0.46) | DYRK1AKDRNUAK1BRD4BRDT | |
| SCHEMBL2928684 | 0.87 | LRRK2 (0.44) | DYRK1AKDRNUAK1BRD4TTK | |
| SCHEMBL2926010 | 0.86 | LRRK2 (0.53) | DYRK1AKDRNUAK1BRD4TTK | |
| SCHEMBL2929459 | 0.86 | VCP (0.45) | DYRK1AKDRNUAK1TTKLRRK2 | |
| SCHEMBL2930971 | 0.86 | DYRK1A (0.47) | DYRK1AKDRNUAK1BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | DYRK1A 498/4885KDR 3834/4885NUAK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.